In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors

Journal of Pediatric Hematology/oncology
S WeitmanD D Von Hoff

Abstract

This study determined the in vitro antitumor activity of a rebeccamycin analog (NSC# 655649) using tetrazolium/formazan (MTT) and clonogenic assays against established pediatric cell lines and solid tumor specimens obtained from children. Tumor cells from 14 established cell lines and 20 patient specimens were exposed in vitro for 1 hour to NSC# 655649 at concentrations ranging from 0.015 to 15.0 microM. The cytotoxicity (IC50) of this agent against established cell lines was determined using both the MTT (cytotoxic) and clonogenic/soft agar cloning (cytostatic) assays. Tumor specimens from children undergoing biopsy or surgical resection were also evaluated in vitro against NSC# 655649 using the clonogenic assay. For studies using patient specimens, antitumor activity was measured by comparing the number of tumor colonies from NSC# 655649-treated cells with those from solvent-treated controls. These studies showed that the mean IC50S using the MTT and clonogenic assays using established solid tumor cell lines were 0.94 and 0.51 microM, respectively. In general, for cell lines tested using both types of assays, the clonogenic assay resulted in a smaller IC50. The overall in vitro responses (< or = 50% survival compared to contr...Continue Reading

References

Oct 1, 1977·The Journal of Clinical Investigation·A Hamburger, S E Salmon
Jul 29, 1977·Science·A G Kendall, R E Tashian
Jul 29, 1977·Science·A W Hamburger, S E Salmon
Jan 1, 1990·The Journal of Antibiotics·T KanekoT Doyle
Jan 17, 1990·Journal of the National Cancer Institute·D D Von HoffF M Muggia
Jan 1, 1986·The American Journal of Pediatric Hematology/oncology·G L MorrisD D Von Hoff
May 1, 1987·The Journal of Antibiotics·J A BushK Tomita
Jan 1, 1985·Cancer Investigation·A R Hanauske, D D Von Hoff
Mar 15, 1996·Cancer·E Brown, M Markman

❮ Previous
Next ❯

Citations

May 15, 2002·European Journal of Medicinal Chemistry·Christelle MarminonMichelle Prudhomme
Aug 26, 2000·Journal of Pediatric Hematology/oncology·S WeitmanD Von Hoff
Jul 9, 2003·Journal of Pediatric Hematology/oncology·Anne-Marie LangevinUNKNOWN Pediatric Oncology Group Study
Nov 4, 2016·Expert Opinion on Investigational Drugs·M TampelliniG V Scagliotti
May 13, 2003·Chembiochem : a European Journal of Chemical Biology·Michaël FacompréChristian Bailly
Jul 5, 2007·Pediatric Blood & Cancer·Anne-Marie LangevinUNKNOWN Children's Oncology Group
Sep 23, 2010·Pediatric Blood & Cancer·Nisha C KakodkarSusan L Cohn
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A W TolcherE K Rowinsky
Dec 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alejandro D RicartEric K Rowinsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.